SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — George H. W. Bush

PatientGeorge H. W. Bush
Date of birth1959-06-12
IdentifiersMRN HR-ML018-SYN; SSN (made up) 000-18-7245
Document date2026-07-17
AuthorDouglas Whitford, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Seven-week review after radioactive iodine. [S]

History of Present Illness

Mr. Bush returns seven weeks after radioactive iodine. He stopped methimazole three days before the treatment and has not restarted it. For about two weeks he has felt more tired in the afternoons, a little cold in air-conditioned rooms, and slightly constipated, and he has regained 2.2 kg. He has had no palpitations, and his home pulse checks have been regular. He takes metoprolol and apixaban every day, with no bleeding. He has started running again, two miles three days a week, without symptoms. He has no neck pain, eye symptoms, or swallowing trouble. He knows of no snoring and has no daytime sleepiness. [S]

ElementDetail
Since radioactive iodineTiredness, mild cold intolerance, and constipation for about two weeks; weight up 2.2 kg
RhythmNo palpitations; regular pulse on home checks
Apixaban safetyNo bleeding; no missed doses
ActivityRunning two miles three days a week
SleepNo snoring or daytime sleepiness

Review of Systems

SystemResultFinding
ConstitutionalPositiveAfternoon tiredness and mild cold intolerance; weight up 2.2 kg
GastrointestinalPositiveMild constipation
CardiovascularNegativeNo palpitations, chest pain, or lightheadedness
EyesNegativeNo grittiness, pain, or double vision

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital)One tablet each morningOral route2026-05-05 to 2026-07-17stoppedS
Metoprolol succinate extended-release 25 mg oral tablet, one tablet by mouth daily (taper)One tablet each morning for eight weeks, then stopOral route2026-07-17 to 2026-09-11stoppedS
Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital)One tablet twice dailyOral route2026-05-05 to 2026-09-11stoppedS
Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth dailyTwo tablets once daily; stop three days before radioactive iodineOral route2026-05-08 to 2026-05-26completedS
Levothyroxine 75 mcg oral tablet, one tablet by mouth daily before breakfastOne tablet on an empty stomach 30 to 60 minutes before breakfastOral route2026-07-17 to 2026-09-11stoppedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-17Body height188cmS
2026-07-17Body weight88.6kgS
2026-07-17Body mass index (BMI) [Ratio]25.1kg/m2S
2026-07-17Systolic blood pressure128mm[Hg]S
2026-07-17Diastolic blood pressure76mm[Hg]S
2026-07-17Heart rate64/minS
2026-07-17Respiratory rate14/minS
2026-07-17Body temperature36.6CelS
2026-07-17Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-17Thyrotropin [Units/volume] in Serum or Plasma5.6m[IU]/L0.4-4 mIU/LHighS
2026-07-17Thyroxine (T4) free [Mass/volume] in Serum or Plasma0.6ng/dL0.8-1.8 ng/dLLowS
2026-07-17Triiodothyronine (T3) [Mass/volume] in Serum or Plasma78ng/dL80-200 ng/dLLowS

Physical Exam

Vital signs recorded on 2026-07-17; see the Vital Signs section. [S]

SystemFinding
GeneralWell; calm
EyesNo lid retraction or proptosis
NeckThyroid smaller and non-tender
CardiovascularRegular rhythm at 64 per minute
NeurologicalNo tremor; ankle reflexes slightly slow to relax

Problems

ProblemClinical statusVerificationCodeProvenance
Paroxysmal atrial fibrillation, first detected four days before intake while running, triggered by hyperthyroidism; CHA2DS2-VASc 1; synthetic modern episode linked to his documented atrial fibrillationactiveconfirmed I48.0S — Synthetic modern classification of a documented arrhythmia.
Graves' disease with hyperthyroidism; synthetic modern diagnosis linked to his documented Graves' diseaseactiveconfirmed E05.00S — Synthetic modern diagnosis confirmed by thyroid tests and TSH receptor antibody; the historical diagnosis is D.
Hypothyroidism after radioactive iodine, on levothyroxine replacementactiveconfirmed E89.0S — Synthetic modern diagnosis linked to his documented hypothyroidism and lifelong thyroid hormone.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationHeart rate and rhythmEvery visitCompleted today64 per minute, regular
ExaminationBlood pressureEvery visit; target below 130/80Completed today128/76 mmHg
ExaminationWeight and BMIEvery visitCompleted today88.6 kg, BMI 25.1; up 2.2 kg
SurveyAtrial fibrillation symptomsEvery visitCompleted todayNone
ImagingAmbulatory rhythm monitoringAs symptoms or decisions requireOrdered14-day ECG patch in about five weeks, to confirm sinus rhythm before the anticoagulation decision
Medication safetyAnticoagulant adherence and bleedingEvery visitCompleted todayNo missed doses; no bleeding
SurveyCHA2DS2-VASc and HAS-BLEDYearly and with any change in clinical statusUp to dateUnchanged: CHA2DS2-VASc 1, HAS-BLED 1
Self-managementAlcohol, tobacco, and physical activityEvery visitCompleted todayNo alcohol; never used tobacco; running two miles three days a week
SurveySleep apnea symptom screenAt diagnosis and at least yearlyCompleted todaySTOP-BANG 2: low risk; no sleep study needed. Completed two months late; no harm resulted, as the screen is negative. Corrective action: the screen is now on the atrial fibrillation intake checklist
LaboratoryFree T4 and total T3 after radioactive iodineWithin one to two months of treatment, then every four to six weeks until stableCompleted todayFree T4 0.6 ng/dL and total T3 78 ng/dL, both low; TSH 5.6 mIU/L
SurveyHypothyroid and overtreatment symptomsEvery visit during titrationCompleted todayTiredness, cold intolerance, and constipation; no palpitations or tremor
LaboratoryTSH after starting levothyroxineFour to eight weeks after each dose changeDueDue in eight weeks
Medication safetyLevothyroxine timing and interactionsAt the start of treatment and with new medicinesCompleted todayTaken alone on an empty stomach; no calcium, iron, or acid-suppressing medicine

Goal progress:

Guideline basis: 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023); 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016); Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (2014); CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026)

Follow-up: Thyroid tests and review in eight weeks, after the 14-day ECG patch. Next scheduled visit 2026-09-11: four-month review: levothyroxine titration and anticoagulation decision. [S]